Pulmocide

Developer of inhaled antifungal medicines for treating respiratory lung infections

placeLondon, England, United Kingdom calendar_todayFounded 2013 groups9 employees language pulmocide.com

Registered entities

Innovation

7 patent families (6 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 804 times.

YearFilings
20164
20176
20184
20194
20204
20213
20223
20234
20241
20253
20261

Social engagement

Social engagement: 2.1K social following, 1 post in the last 12 months — below the industry typical range.

Investor mix

17 investors on record; lead investors include SR One, Jeito, Cystic Fibrosis Foundation, Vivo Capital.

Investor typeCountShare
Venture capital953%
Private equity16%
Accelerator & incubator16%
Bank & private debt16%
Other / undisclosed529%
Coming soon